Avian Influenza

Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on CEL-SCI Corporation

Avian Influenza Library Library Home This article was published in Pain & Central Nervous System Week, which you can subscribe to online.

CEL-SCI Corporation develops immune-based cancer and infectious disease therapies. Its primary product candidate is Multikine(R), a next-generation, comprehensive immunotherapy that targets treatment-naive, newly diagnosed head and neck cancer. Multikine(R) is a mixture of biologically active natural cytokines designed to closely mimic the natural immune system.

Differing from other immunotherapies, Multikine(R) has the following attributes: (1) multitargeted-it activates multiple cellular components of the immune system to fight cancer; (2) administered as a first-line therapy before the patient receives surgery, chemotherapy, or radiotherapy, which is when the immune system is strongest; (3) kills roughly 50% of tumor cells before the standard of care is begun; (4) renders the residual live cancer cells that survive treatment more susceptible to the effects of radiation and chemotherapy, thereby potentially enhancing these treatments; and (5) is shown to be safe and well tolerated in Phase I and II clinical trials. In over 200 patients treated in CEL-SCI's trials, no severe side effects associated with Multikine(R) were reported.

Multikine(R) is now ready for a Phase III clinical trial for advanced primary head and neck cancer. In Phase III, CEL-SCI intends to administer Multikine(R) prior to the currently accepted and routinely used first-line standard of care treatment-surgery followed by radiation/chemotherapy. The Company hopes to show that Multikine(R) plus the standard of care increases patients' overall survival. CEL-SCI believes that a positive Phase III outcome could enable Multikine(R) to be routinely included as part of the standard of care for all advanced primary head and neck cancer patients. Multikine(R) may also have applications in melanoma and breast, skin, bladder, and cervical cancer.

Also in CEL-SCI's pipeline are two other platforms, a Ligand Epitope Antigen Presentation System (L.E.A.P.S.)(TM) and Antigen-Directed Apoptosis (AdapT), with a second product candidate, CEL-1000. CEL-1000, derived from L.E.A.P.S.(TM), is poised for trials as a potential adjuvant to boost vaccine immunogenicity for viral encephalitis, herpes simplex, malaria, hepatitis B, and the avian flu.

Keywords: Avian Flu, Avian Influenza, Biological Therapy, Bird Flu, Cancer Vaccines, Central Nervous System Disease, Cervical Cancer, Cervical Carcinoma, Chemotherapy, Drug Therapy, Encephalitis, Gastroenterology, Head and Neck Cancer, Head and Neck Neoplasms, Hepatitis, Immunotherapy, Infectious Disease, Malaria, Oncology, Treatment, Viral Encephalitis, Women's Health, Crystal Research Associates Llc.

This article was prepared by Pain & Central Nervous System Week editors from staff and other reports. Copyright 2007, Pain & Central Nervous System Week via NewsRx.com.